Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

Written By Chris Nadeau
Chris Nadeau
Next

Wingspan Raises $24M Series B to Scale Embedded Contractor Management and Capture $1.4T Market